The Phase 2b SOOTHE and Phase 2a BLUEPRINT clinical trials are on track, with topline results expected in Q4 2021 – BELLUS Health Inc. a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related disorders, today reported its financial and operating results for the second quarter ending June 30, 2021. PROGRAM AND CORPORATE …
– The Phase 2b SOOTHE and Phase 2a BLUEPRINT clinical trials are on track, with topline results expected in Q4 2021 –
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related disorders, today reported its financial and operating results for the second quarter ending June 30, 2021.
PROGRAM AND CORPORATE HIGHLIGHTS
Ongoing Phase 2b SOOTHE clinical trial of BLU-5937 in patients with refractory chronic cough (“RCC”).
- As of August 2021, the SOOTHE trial has achieved approximately 80% of its enrollment target of 300 patients.
- A pre-specified, blinded Sample Size Re-Estimation (“SSRE”) analysis has been conducted, and no changes have been made to the SOOTHE trial size.
- We expect topline results in the fourth quarter of 2021.
- We expect to conduct an administrative interim analysis in September 2021.
Ongoing Phase 2a BLUEPRINT clinical trial of BLU-5937 in patients with chronic...
Read Full Story: https://investingnews.com/news/biotech-investing/bellus-health-reports-second-quarter-2021-financial-results-and-business-highlights/
Your content is great. However, if any of the content contained herein violates any rights of yours, including those of copyright, please contact us immediately by e-mail at media[@]kissrpr.com.